These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 36945819)

  • 1. Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight-based dosed valganciclovir prophylaxis.
    Liverman R; Serluco A; Nance G; George R; Rodriguez DS; Deshpande S; Mao C; Garro R; Yildirim I
    Pediatr Transplant; 2023 Jun; 27(4):e14493. PubMed ID: 36945819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early cytomegalovirus DNAemia and antiviral dose adjustment in high vs intermediate risk kidney transplant recipients.
    Schaenman J; Phonphok K; Spanuchart I; Duong T; Sievers TM; Lum E; Reed EF; Bunnapradist S
    Transpl Infect Dis; 2021 Feb; 23(1):e13457. PubMed ID: 32892447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiology and long-term outcomes of cytomegalovirus DNAemia and disease in pediatric solid organ transplant recipients.
    Valencia Deray KG; Hosek KE; Chilukuri D; Dunson JR; Spielberg DR; Swartz SJ; Spinner JA; Leung DH; Moulton EA; Munoz FM; Demmler-Harrison GJ; Bocchini CE
    Am J Transplant; 2022 Jan; 22(1):187-198. PubMed ID: 34467658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus and Epstein-Barr virus infections among pediatric kidney transplant recipients at a center using universal Valganciclovir Prophylaxis.
    Paulsen G; Cumagun P; Mixon E; Fowler K; Feig D; Shimamura M
    Pediatr Transplant; 2019 May; 23(3):e13382. PubMed ID: 30786115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients: A Prospective Pharmacokinetic Study.
    Peled O; Berkovitch M; Rom E; Bilavsky E; Bernfeld Y; Dorfman L; Pappo A; Ziv-Baran T; Brandriss N; Bar-Haim A; Amir J; Ashkenazi-Hoffnung L
    Pediatr Infect Dis J; 2017 Aug; 36(8):745-750. PubMed ID: 28383392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus infection and allograft rejection among pediatric heart transplant recipients in the era of valganciclovir prophylaxis.
    Das BB; Prusty BK; Niu J; Sue PK
    Pediatr Transplant; 2020 Dec; 24(8):e13750. PubMed ID: 32573886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real world experience with conversion from valganciclovir to letermovir for cytomegalovirus prophylaxis: Letermovir reverses leukopenia and avoids mycophenolate dose reduction.
    Jorgenson MR; Descourouez JL; Saddler CM; Smith JA; Odorico JS; Rice JP; Mandelbrot DA
    Clin Transplant; 2023 Dec; 37(12):e15142. PubMed ID: 37755141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body surface area compared to body weight dosing of valganciclovir is associated with increased toxicity in pediatric solid organ transplantation recipients.
    Demirhan S; Munoz FM; Valencia Deray KG; Bocchini CE; Danziger-Isakov L; Blum S; Sharma TS; Sherman G; Boguniewicz J; Bacon S; Ardura MI; Maron GM; Ferrolino J; Foca M; Herold BC
    Am J Transplant; 2023 Dec; 23(12):1961-1971. PubMed ID: 37499799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-Dose Valganciclovir Prophylaxis Is Safe and Cost-Saving in CMV-Seropositive Kidney Transplant Recipients.
    Shi Y; Lerner AH; Rogers R; Vieira K; Merhi B; Mecadon K; Osband AJ; Bayliss G; Gohh R; Morrissey P; Farmakiotis D
    Prog Transplant; 2021 Dec; 31(4):368-376. PubMed ID: 34839729
    [No Abstract]   [Full Text] [Related]  

  • 10. Cytomegalovirus infection in heart transplantation: A single center experience.
    Echenique IA; Angarone MP; Rich JD; Anderson AS; Stosor V
    Transpl Infect Dis; 2018 Aug; 20(4):e12896. PubMed ID: 29602266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.
    Limaye AP; Budde K; Humar A; Vincenti F; Kuypers DRJ; Carroll RP; Stauffer N; Murata Y; Strizki JM; Teal VL; Gilbert CL; Haber BA
    JAMA; 2023 Jul; 330(1):33-42. PubMed ID: 37279999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GCV/VCVG prophylaxis against CMV DNAemia in pediatric renal transplant patients: A systematic review and meta-analysis.
    Chatani B; Glaberson W; Nemeth Z; Tamariz L; Gonzalez IA
    Pediatr Transplant; 2019 Sep; 23(6):e13514. PubMed ID: 31210393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A split strategy to prevent cytomegalovirus after kidney transplantation using prophylaxis in serological high-risk patients and a pre-emptive strategy in intermediate-risk patients: Combining the best of two options?
    Hellemans R; Wijtvliet V; Bergs K; Philipse E; Vleut R; Massart A; Couttenye MM; Matheeussen V; Abramowicz D
    Transpl Infect Dis; 2021 Apr; 23(2):e13467. PubMed ID: 32935909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors of spontaneous CMV DNAemia clearance in kidney transplantation.
    Noble J; Gatault P; Sautenet B; Gaudy-Graffin C; Beby-Defaux A; Thierry A; Essig M; Halimi JM; Munteanu E; Alain S; Buchler M
    J Clin Virol; 2018; 99-100():38-43. PubMed ID: 29306112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
    Chaiyapak T; Borges K; Williams A; Banh T; Vasilevska-Ristovska J; Allen U; Parekh RS; Hébert D
    Transplantation; 2018 Aug; 102(8):1391-1396. PubMed ID: 29377877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early versus delayed initiation of cytomegalovirus prophylaxis after liver transplant.
    Magid M; Byrns J; Gommer J; Yang Z; Lee HJ; Harris M
    Pharmacotherapy; 2022 Aug; 42(8):634-640. PubMed ID: 35748517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of a Weight-based Dosing Regimen of Valganciclovir for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients.
    Pappo A; Peled O; Berkovitch M; Bilavsky E; Rom E; Amir J; Krause I; Yarden-Bilavsky H; Scheuerman O; Ashkenazi-Hoffnung L
    Transplantation; 2019 Aug; 103(8):1730-1735. PubMed ID: 31343571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pitfalls in Valganciclovir Prophylaxis Dose Adjustment Based on Renal Function in Kidney Transplant Recipients.
    Hammer N; Hoessly L; Haidar F; Hirzel C; de Seigneux S; van Delden C; Vogt B; Sidler D; Neofytos D
    Transpl Int; 2024; 37():12712. PubMed ID: 38784442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: a systematic review and meta-analysis.
    Kalil AC; Mindru C; Botha JF; Grant WJ; Mercer DF; Olivera MA; McCartan MA; McCashland TM; Langnas AN; Florescu DF
    Liver Transpl; 2012 Dec; 18(12):1440-7. PubMed ID: 22887929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective long-term study on primary CMV infections in adult liver transplant (D+/R-) patients after valganciclovir prophylaxis.
    Lautenschlager I; Loginov R; Mäkisalo H; Höckerstedt K
    J Clin Virol; 2015 Oct; 71():73-5. PubMed ID: 26318605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.